CISPLATIN, DOXORUBICIN AND CYCLOPHOSPHAMIDE IN ADVANCED SALIVARY-GLAND CARCINOMA - A PHASE-II TRIAL OF 22 PATIENTS

Background: To evaluate the activity of CAP regimen in advanced saliva ry gland carcinomas. Patients and methods: Twenty-two patients with ad vanced salivary gland carcinomas were treated according to the CAP reg imen. All patients were previously treated with surgery and/or radioth erapy and/or chemotherapy. Seven patients had local or locoregional di sease, nine patients had local and metastatic disease, six patients ha d metastatic disease only. The most common histologies were included. Results: Of 22 patients, six achieved a partial response (27%, 95% CI: 11%-50%): no complete response was observed. Response duration ranged between 3 and 13 months (median seven months). The median survival ti me for the entire series was 21 months. Conclusions: In this investiga tion, on 22 consecutive patients, CAP combination provided an overall response rate of 27%. This study confirms that, at present, available drugs yield poor results, either as single agents or as combination th erapy.